statistiche ricercatore

ACCOLLA, ROBERTO

Distribuzione geografica

Continente	#
NA - Nord America	25.449
EU - Europa	16.326
AS - Asia	10.040
SA - Sud America	1.002
Continente sconosciuto - Info sul continente non disponibili	225
AF - Africa	151
OC - Oceania	25
Totale	53.218

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	25.051
IT - Italia	7.783
SG - Singapore	3.178
UA - Ucraina	2.755
CN - Cina	2.258
VN - Vietnam	1.518
TR - Turchia	1.424
DE - Germania	1.290
SE - Svezia	1.083
HK - Hong Kong	1.063
BR - Brasile	856
FI - Finlandia	747
IE - Irlanda	665
FR - Francia	607
GB - Regno Unito	542
RU - Federazione Russa	484
CA - Canada	238
IN - India	188
MX - Messico	118
BD - Bangladesh	91
PL - Polonia	82
JP - Giappone	78
NL - Olanda	63
AR - Argentina	56
ES - Italia	50
BE - Belgio	48
NG - Nigeria	44
ZA - Sudafrica	44
IQ - Iraq	39
PK - Pakistan	35
LT - Lituania	25
AT - Austria	20
AU - Australia	19
EC - Ecuador	18
KR - Corea	17
VE - Venezuela	17
AE - Emirati Arabi Uniti	16
MA - Marocco	15
PY - Paraguay	15
CO - Colombia	14
CZ - Repubblica Ceca	14
SA - Arabia Saudita	14
MY - Malesia	13
CH - Svizzera	12
EU - Europa	12
PH - Filippine	12
KE - Kenya	11
JO - Giordania	10
UZ - Uzbekistan	10
CL - Cile	9
DZ - Algeria	9
ID - Indonesia	9
JM - Giamaica	9
NP - Nepal	9
PE - Perù	9
EG - Egitto	8
IR - Iran	8
TN - Tunisia	8
BY - Bielorussia	6
MD - Moldavia	6
CR - Costa Rica	5
DO - Repubblica Dominicana	5
HN - Honduras	5
LB - Libano	5
NZ - Nuova Zelanda	5
PS - Palestinian Territory	5
TT - Trinidad e Tobago	5
TW - Taiwan	5
DK - Danimarca	4
GE - Georgia	4
IL - Israele	4
KH - Cambogia	4
NI - Nicaragua	4
RO - Romania	4
RS - Serbia	4
AL - Albania	3
BG - Bulgaria	3
BH - Bahrain	3
CI - Costa d'Avorio	3
GR - Grecia	3
GT - Guatemala	3
GY - Guiana	3
HR - Croazia	3
KZ - Kazakistan	3
LU - Lussemburgo	3
MT - Malta	3
OM - Oman	3
PA - Panama	3
PT - Portogallo	3
AZ - Azerbaigian	2
BN - Brunei Darussalam	2
BO - Bolivia	2
ET - Etiopia	2
GA - Gabon	2
HU - Ungheria	2
LV - Lettonia	2
PR - Porto Rico	2
QA - Qatar	2
TG - Togo	2
TH - Thailandia	2
Totale	52.984

Salva come PNG Salva come JPEG

Città	#
Milan	5.731
Fairfield	2.139
Jacksonville	2.111
San Jose	1.927
Ashburn	1.786
Woodbridge	1.748
Singapore	1.726
Chandler	1.580
Ann Arbor	1.181
Houston	1.174
Hong Kong	1.044
Seattle	913
Wilmington	910
Dallas	824
Izmir	764
Princeton	716
Dearborn	698
Cambridge	694
Dublin	661
Council Bluffs	656
Beijing	608
Nyköping	541
Dong Ket	430
Boardman	429
Rome	423
The Dalles	417
Lauterbourg	315
Chicago	283
New York	254
San Mateo	242
Como	238
Ho Chi Minh City	201
Los Angeles	200
San Diego	167
Santa Clara	159
Orem	142
Ogden	140
Hanoi	137
Helsinki	136
Toronto	122
Guangzhou	117
São Paulo	101
Munich	95
London	90
Düsseldorf	83
Tokyo	76
Mexico City	71
Verona	71
Chennai	70
Warsaw	68
Hefei	64
Shanghai	56
Frankfurt am Main	51
Manchester	50
Brooklyn	49
Kunming	49
Nanjing	49
Brussels	45
Buffalo	44
Abuja	42
Norwalk	42
Hangzhou	40
Amsterdam	39
Montreal	39
Denver	38
Jinan	38
Phoenix	38
Turku	36
Pune	34
Boston	33
Da Nang	33
Stockholm	32
Johannesburg	31
Shenzhen	31
Washington	30
Haiphong	29
Kocaeli	29
Fuzhou	28
San Francisco	28
Memphis	27
Mumbai	27
Atlanta	26
Tianjin	26
Poplar	25
Redwood City	20
Wuhan	20
Zhengzhou	20
Belo Horizonte	18
Columbus	18
Falls Church	18
Nuremberg	18
St Petersburg	18
Changsha	17
Rio de Janeiro	17
Sydney	16
Nanchang	15
Naples	15
Querétaro	15
Auburn Hills	14
Berlin	14
Totale	36.960

Salva come PNG Salva come JPEG

Nome	#
CIITA-driven MHC class ii expressing tumor cells can efficiently prime naive CD4+ TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells	273
Class II Transactivator-Induced MHC Class II Expression in Pancreatic Cancer Cells Leads to Tumor Rejection and a Specific Antitumor Memory Response	268
Boosting the MHC class II-restricted tumor antigen presentation to CD4+ T helper cells: A critical issue for triggering protective immunity and re-orienting the tumor microenvironment toward an anti-tumor state	251
Analysis of the structural heterogeneity and polymorphism of human Ia antigens. Four distinct subsets of molecules are coexpressed in the Ia pool of both DR1,1 homozygous and DR3,W6 heterozygous B cell lines	246
Unsung hero Robert C. Gallo	241
Isolation of cDNA clones for the p33 invariant chain associated with HLA-DR antigens	238
Cytoplasmic Localization of HTLV-1 HBZ Protein: A Biomarker of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)	238
Translation and assembly of HLA-DR antigens in Xenopus oocytes injected with mRNA from a human B-cell line	237
Investigating Human T Cell Lymphotropic Retrovirus (HTLV) tax function with molecular and immunophenotypic techniques	237
Antibody-mediated activation of a deletion-mutant b-galactosidase defective in the a-region	236
Adequate Antigen Availability: A Key Issue for Novel Approaches to Tumor Vaccination and Tumor Immunotherapy	234
CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches	232
Functional significance of polymorphism among MHC class II gene promoters	230
Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response	229
Demonstration at the single cell level of the existence of distinct clusters of epitopes in two predefined human Ia molecular subsets	227
Reactivation by a trans-acting factor of human major histocompatibility complex Ia gene expression in interspecies hybrids between an Ia-negative human B-cell variant and an Ia-positive mouse B-cell lymphoma	227
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4(+) T lymphocytes for immunotherapy	226
Human adipose-derived stem cells promote vascularization of collagen-based scaffolds transplanted into nude mice	226
HTLV-1 HBZ Protein Resides Exclusively in the Cytoplasm of Infected Cells in Asymptomatic Carriers and HAM/TSP Patients	225
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells	219
Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1	219
An enhancer factor defect in a mutant Burkitt lymphoma cell line	218
Cell lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression.	217
Active suppression of major histocompatibility complex class II gene expression during differentiation from B cells to plasma cells.	215
aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression.	214
Typing of a polymorphic human gene conferring susceptibility to insulin-dependent diabetes mellitus by picosecond-resolved FRET on non-purified/non-amplified genomic DNA	214
Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL	213
Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy	212
Transcriptional regulation of MHC class II genes	212
Allogeneic mixed lymphocyte reactions in humans : Pretreatment of either the stimulator or the responder cell population with monoclonal anti-Ia antibodies leads to an inhibition of cell proliferation	210
A girl with Diabetes and severe Combined Immunodeficiency from Adenosine Deaminase Deficiency	210
Distinct HLA-DR epitopes and distinct families of HLA-Dr molecules defined by 15 monoclonal antibodies (mAb) either anti-DR or allo-anti-Iak cross-reacting with human DR molecule. I. Cross-inhibition studies of mAb cell surface fixation and differential binding of mAb to detergent-solubilized HLA molecules immobilized to a solid phase by a first mAb	209
Host defense mechanisms against pathogens	209
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory.	208
Sandwich enzyme immunoassay using three monoclonal antibodies against different epitopes of carcinoembryonic antigen "CEA".	207
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory	207
The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators	207
The MHC-II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation	207
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific anti-tumor memory	206
Divergent evolution in the mechanisms controlling major histocompatibility complex class II gene transcription in mouse and human	206
The MHC class II transactivator: prey and hunter in infectious diseases	205
In vivo modification of major histocompatibility complex class II DRA promoter occupancy mediated by the AIR-1 trans-activator	205
The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells	205
Antibody-mediated activation of genetically defective Escherichia coli beta-galactosidases by monoclonal antibodies produced by somatic cell hybrids	204
H2-RESTRICTED RECOGNITION OF CLONED HLA CLASS-I GENE-PRODUCTS EXPRESSED IN MOUSE CELLS	204
Double-stranded deoxyribonucleic acid binds to HLA class II molecules and inhibits HLA class II-mediated antigen presentation	203
Detection of human chromosomes in somatic cell hybrids by PCR analysis	203
Ia-negative B-cell variants reveal a coordinate regulation in the transcription of the HLA class II gene family	202
APC gene mutations and allelic losses in sporadic ampullary tumours: evidence of genetic difference from tumours associated with familial adenomatous polyposis	201
Biochemical aspects of human Ia molecules	199
Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells	199
Binding of one monoclonal antibody to human Ia molecules can be enhanced by a second monoclonal antibody	197
Picosecond-resolved FRET on non-amplified DNA for identifying individuals genetically susceptible to type-1 diabetes	197
The MHC Class II transactivator CIITA inhibits the persistent activation of NF-kB by Tax-1	197
Localization, quantization and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL	196
Monoclonal antibodies against carcinoembryonic antigen (CEA) used in solid-phase enzyme immunoassay	195
Analisi dell’espressione genica in cellule epiteliali umane trattate con la proteina Tat di HIV	194
The importance of cross-reactions between species: mouse allo-anti-Ia monoclonal antibodies as a powerful tool to define human Ia subsets	194
CIITA-driven MHC class II expressing tumor cells as antigen presenting cell performers: Toward the construction of an optimal anti-tumor vaccine	194
Autoimmunità e Malattie Autoimmuni	192
IL-2 mediated T cell proliferation in humans is blocked by a monoclonal antibody directed against monomorphic determinants of HLA-DR antigens.	191
Distinct forms of both a and b subunits are present in the human Ia molecular pool	190
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.	190
SUSCEPTIBILITY OF HUMAN-MOUSE T-CELL HYBRIDS TO HIV-PRODUCTIVE INFECTION	190
Molecular and cellular correlates of the CIITA-mediated inhibition of HTLV-2 Tax-2 transactivator function resulting in loss of viral replication	189
Subsets of human Ia-like molecules defined by monoclonal antibodies	188
Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines.	187
Somatic cell hybrids producing antibodies specific to human fibronectin.	187
Enterovirus infection and low Treg function: two possible biomarkers of progression to autoimmune T1D.	187
Analysis of the antigen specific T cell repertoire in HIV infection	187
Evidence for a trans-acting activator function regulating the expression of the human CD5 antigen	185
Adequate Antigen Availability (AAA) in antitumor immunity: Definition and consequences for novel strategies of tumor prevention and antitumor treatment	185
Reducing the global burden of HTLV-1 infection: An agenda for research and action	185
A family of trans-acting factors with distinct regulatory functions control expression of MHC class II genes.	184
Stable integration of mouse DNA into Ia-negative human B-lymphoma cells causes reexpression of the human Ia-positive phenotype.	184
New strategies of mammary cancer vaccination	183
Superinfection by Epstein-Barr virus of a subset of Raji cells is independent of HLA class-II antigens	183
Expression of HLA-DR antigen in human class II mutant B-cell lines by double infection with retrovirus vectors.	182
Assessment of the DQB1-DQA1 complete genotype allows best prediction for IDDM	181
Tumor Immunology meets Immunology: Modified cancer cells as professional APC for priming naÃ¯ve tumor-specific CD4+ T cells	181
The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication	180
ras-Family gene mutations in neoplasia of the ampulla of Vater	178
Insight into the molecular mechanism of CIITA-mediated inhibition of HIV-1 and HTLV transactivators	178
The MHC class II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation.	178
Structural analysis of the CD69 early activation antigen by two monoclonal antibodies directed to different epitopes.	177
A dual defensive role of CIITA against retroviral infections	177
The MHC-II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation	177
THE HUMAN IA-ASSOCIATED INVARIANT CHAIN IS SYNTHESIZED IN IA-NEGATIVE B-CELL VARIANTS AND IS NOT EXPRESSED ON THE CELL-SURFACE OF BOTH IA-NEGATIVE AND IA-POSITIVE PARENTAL CELLS	177
Neonatal Fc receptor is involved in the protection of fibrinogen after its intake in peripheral blood mononuclear cells	177
Tripartite motif 22 and class II transactivator restriction factors: Unveiling their concerted action against retroviruses	176
Interspecies somatic T cell hybrids as biological tools for studying gene expression during T cell development	175
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.	172
The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T cell Lymphotropic virus type 1.	172
Isolation of cDNA clones encoding HLA-DR a chains	171
Idiotype-specific neonatal suppression of phosphorylcholine-responsive B cells.	171
The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2	171
MHC: Orchestrating the immune response	171
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma	171
Time-Resolved Förster Resonance Energy Transfer Analysis of Single-Nucleotide Polymorphisms: Towards Molecular Typing of Genes on Non-Purified and Non-PCR-Amplified DNA	170
Trans-acting element(s) operating across species barriers positively regulate expression of major histocompatibility complex class II genes.	168
Totale	20.152

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	204.023
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	204.023

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	2.837	0	414	271	231	114	95	124	219	150	468	278	473
2022/2023	4.358	470	150	270	468	343	947	6	640	633	135	167	129
2023/2024	8.694	1.434	1.405	1.535	1.536	1.645	542	64	110	272	44	18	89
2024/2025	4.898	53	74	928	149	222	235	218	321	563	300	402	1.433
2025/2026	11.774	763	658	542	1.610	1.087	799	2.785	742	1.262	728	508	290
2026/2027	755	264	491	0	0	0	0	0	0	0	0	0	0
Totale													53.218